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Abstract: Objective: To investigate whether artificial tears and cold compress alone or in combination 
provide a treatment benefit, whether they were as effective as, or could enhance topical anti-allergic 
medication.   
Design: Randomized masked clinical trial. 
Participants: Eighteen subjects (aged 29.5 ± 11.0 years) allergic to grass pollen  
Intervention: Controlled exposure to grass pollen using an environmental chamber to stimulate an 
ocular allergic reaction followed by artificial tears (AT), 5 minutes of cold compress (CC), AT combined 
with CC, or no treatment applied at each separate visit in random order. A subset of 11 subjects also 
had epinastine (EH) applied alone and combined with CC in random order or instillation of a volume 
matched saline control.   
Main Outcome Measures: bulbar conjunctival hyperemia, ocular surface temperature, ocular symptoms 
repeated before and every 10 minutes after treatment for 1 hour 
Results: Bulbar conjunctival hyperemia and ocular symptoms decreased and temperature recovered to 
baseline faster with non-pharmaceutical treatments compared to no treatment (p < 0.05). AT 
combined with CC reduced hyperemia more than other treatments (p < 0.05). The treatment effect of 
EH was enhanced by combining it with a CC (p < 0.001). CC combined with AT or EH lowered the 
antigen-raised ocular surface temperature below the pre-exposure baseline. AT instillation alone or CC 
combined with AT or EH significantly reduced the temperature (p < 0.05). CC combined with AT or EH 
had a similar cooling effect (p > 0.05). At all measurement time intervals, symptoms were reduced for 
both EH and EH combined with CC than CC or AT alone or in combination (p < 0.014).  
Conclusions: In a controlled exposure to grass pollen, cold compresses and artificial tears showed 
therapeutic effect on the signs and symptoms of allergic conjunctivitis. A cold compress enhanced the 
use of epinastine alone and was the only treatment to reduce symptoms to baseline within an hour of 
antigenic challenge. Signs of allergic conjunctivitis were generally reduced most by a combination of a 
cold compress in combination with artificial tears or epinastine. 
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Thank you for revising your manuscript. In reviewing your revisions, I have only a couple of 
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P 7, LM 170 and multiple places elsewhere (including P 8, LM 193; 
P 8, LM 201): When comparing 2 variables, use the term "between;" when comparing 3 or more 
variables, use the term "among." 
 
I suspect that what the reviewer was trying to point out is that Strunk and White, in "The Elements 
of Style", recommend the following as regards the use of "among" and "between": "When more 
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Precis 
Non-pharmaceutical treatments for acute presentation seasonal allergic conjunctivitis were found to 
be as efficacious in relieving the signs and symptoms of the ocular allergic response as a dual action 
antihistamine mast cell stabilizer. 
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Abstract 24 
Objective: To investigate whether artificial tears and cold compress alone or in combination 25 
provide a treatment benefit, whether they were as effective as, or could enhance topical anti-26 
allergic medication.   27 
Study Design: Randomizsed masked clinical trial. 28 
Participants: Eighteen subjects (aged 29.5 ± 11.0 years) allergic to grass pollen  29 
Intervention: Controlled exposure to grass pollen using an environmental chamber to 30 
stimulate an ocular allergic reaction followed by artificial tears (AT), 5 minutes of cold 31 
compress (CC), AT combined with CC, or no treatment applied at each separate visit in 32 
random order. A subset of 11 subjects also had epinastine (EH) applied alone and combined 33 
with CC in random order or instillation of a volume matched saline control.   34 
Main Outcome Measures: bulbar conjunctival hyperemia, ocular surface temperature, ocular 35 
symptoms repeated before and every 10 minutes after treatment for 1 hour 36 
Results: Bulbar conjunctival hyperemia and ocular symptoms decreased and temperature 37 
recovered to baseline faster with non-pharmaceutical treatments compared to no treatment 38 
(p < 0.05). AT combined with CC reduced hyperemia more than other treatments (p < 0.05). 39 
The treatment effect of EH was enhanced by combining it with a CC (p < 0.001). CC 40 
combined with AT or EH lowered the antigen-raised ocular surface temperature below the 41 
pre-exposure baseline. AT instillation alone or CC combined with AT or EH significantly 42 
reduced the temperature (p < 0.05). CC combined with AT or EH had a similar cooling effect 43 
(p > 0.05). At all measurement time intervals, symptoms were reduced for both EH and EH 44 
combined with CC than CC or AT alone or in combination (p < 0.014).  45 
Conclusions: In a controlled exposure to grass pollen, cold compresses and artificial tears 46 
showed therapeutic effect on the signs and symptoms of allergic conjunctivitis. A cold 47 
compress enhanced the use of epinastine alone and was the only treatment to reduce 48 
symptoms to baseline within an hour of antigenic challenge. Signs of allergic conjunctivitis 49 
were generally reduced most by a combination of a cold compress in combination with 50 
artificial tears or epinastine. 51 
  52 
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Ocular allergy represents a group of hypersensitivity disorders that primarily affects the 53 
conjunctiva. The most common form of ocular allergy is seasonal allergic conjunctivitis 54 
(SAC), accounting for 90% of cases 1, 2. The most prevalent allergens in SAC are grass, tree, 55 
and weed pollen and outdoor moulds 2.  In the United Kingdom (UK), the prevalence of 56 
ocular allergy to grass pollen in patients attending optometric practice is estimated to be 8% 57 
3. Although the signs and symptoms of SAC are usually mild, it may hinder school 58 
performance, work productivity and everyday tasks such as driving 4, 5, 6. 59 
  60 
The primary treatment strategy for SAC involves avoidance of the offending allergen to 61 
prevent the initiation of the allergic response. However, complete avoidance is not often 62 
possible and use of topical anti-allergic medications is required when signs and symptoms 63 
occur 7, 8, 9. It has been suggested that non-pharmacological treatments such as artificial 64 
tears and cold compresses may be used in conjunction with allergen avoidance strategies 65 
and anti-allergic medications to help bring about symptomatic relief 9, 10, 11, 12. However, there 66 
appears to be no evidence in the scientific literature which demonstrates the efficacy of 67 
using artificial tears or cold compresses for treating SAC. Therefore the aim of this study was 68 
to investigate the efficacy of instillation of artificial tear substitutes (AT) and application of 69 
cold compresses (CC) alone and in combination in patients with confirmed ocular allergic 70 
sensitivity to a controlled exposure of grass pollen using an environmental chamber model. 71 
In addition, the effectiveness of these treatments compared to a topical dual action 72 
antihistamine-mast cell stabilizer licensed for the treatment of SAC alone and in combination 73 
with CC was investigated.  74 
 75 
  76 
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Materials and& Methods 77 
The study received ethical approval from the Aston University Research Ethics Committee 78 
and was registered as a clinical trial (NCT01569191 ClinicalTrials.gov). The research was 79 
conducted in accordance this the principles expressed in the Declaration of Helsinki. 80 
 81 
Subjects  82 
All participants were ≥18 years old volunteers from a University population with no history of 83 
asthma, any active eye pathology and were not using ocular or systemic medications known 84 
to affect the eye. None of the participants experienced any form of allergic conjunctivitis at 85 
least 1 month before the study took place or used anti-allergic medication over the 14 days 86 
prior to testing.  87 
 88 
Screening Protocol 89 
Subjects underwent skin prick (SPT) and bilateral conjunctival challenge tests (CCT) to 90 
confirm systemic and ocular allergic sensitivity to grass pollen 13, 14, 15 . SPT was performed 91 
on the forearm using grass pollen solution (10 HEP, Soluprick SQ, ALK-ABELLO, Denmark) 92 
and positive (histamine solution) and negative (saline) controls. After 20 minutes, the size of 93 
the wheal response was measured and a positive result was recorded for diameters ≥3mm.  94 
CCT was performed by applying 20µL of grass pollen (Soluprick SQ, ALK-ABELLO, 95 
Denmark) solution in two-fold increasing concentrations from 3IR/mL to 100IR/mL to one eye 96 
(selected at random to be the experimental eye) and saline solution to the contralateral 97 
(control) eye every 10 minutes until a composite score of ≥5 using a standardized scoring 98 
method was reached 13, 14, 16.  Eligible subjects who had a positive SPT and CCT proved 99 
sensitivity to grass pollen were enrolled into the study with written informed consent.  100 
 101 
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Eighteen subjects (one third male) took part in the study with a mean age of 29.5±11.0 (age 102 
range 20-65). At each visit subjects underwent slit lamp bio-microscopy to ensure signs and 103 
symptoms of SAC were not present prior to testing. This was followed by a series of 104 
measurements on both eyes including slit lamp examination and grading of nasal and 105 
temporal bulbar conjunctival hyperemia using a grading scale (Jenvis Research, Germany), 106 
and ocular surface temperature of the cornea and temporal and nasal bulbar conjunctiva 107 
(5mm2 area, 2 seconds post-blink) using an infra-red camera (Thermo Tracer TH7102, NEC, 108 
Japan) where a series of digital markers were used to ensure the temperature was 109 
measured at the same location for each subject17. Ocular allergy symptomology was also 110 
measured using the eye symptom section from the Rhinoconjunctivitis Quality of Life 111 
Questionnaire (RQLQ) on a 0 to 6 scale, with the summed score for itching, watering, 112 
swelling and soreness resulting in a score between 0 and 24  18.  113 
 114 
Subjects were exposed to between 251 and 500 grains/m3 of Timothy grass pollen (phleum 115 
pratense; equivalent to a “very high” pollen count classification; concentration monitored 116 
using a Burkard continuous air sampler) in a computer controlled environmental chamber 117 
(Design Environmental, 32 Rassau Industrial Estate, Ebbw Vale, Gwent) at a temperature of 118 
20°C and 70% ambient humidity (average local conditions in June in the UK) on separate 119 
visits with the concentration established that caused ocular itching graded ≥3 (RQLQ grade) 120 
and a ≥0.5 unit change (Jenvis scale) in nasal and temporal bulbar conjunctival hyperemia 121 
occurred in both eyes after 5 minutes of exposure.  122 
 123 
Once the concentration of pollen for each individual had been established, on separate 124 
occasions separated by at least one week, out of the allergy season, the subjects had 125 
baseline measurements taken and were then exposed to pollen at this concentration for 5 126 
minutes and 5 minutes post exposure the same measurements were repeated. This was 127 
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followed by application bilaterally of either an AT applied to the temporal conjunctiva (Blink 128 
Refreshing Eye Drops 0.5ml single use vial, Abbot Medical Optics, USA), CC applied to the 129 
closed eye lid for 5 minutes (frozen gel-pack: Boots Pharmaceuticals, Nottingham, UK), AT 130 
combined with CC (for 5 minutes, 5 minutes after AT instillation) or no treatment (NT) to the 131 
eyes in random order (computer generated) at each visit (examiner masked). The same 132 
measures were then repeated every 10 minutes for 1 hour at each visit.  133 
 134 
A subgroup of 11 randomly selected subjects (mean age of 29.1±12.9 years, range 20-65) 135 
attended for three further identical visits receiving 1 drop of Epinastine Hydrochloride (EH, 136 
Relestat 0.5mg/ml, Allergan, USA), 1 drop of EH combined with CC (for 5 minutes, 5 137 
minutes after instillation of EH), or a single drop of saline (termed vehicle, equivalent to the 138 
same volume as the drug but without the active ingredients to determine how much of the 139 
effect was lubrication compared to pharmaceutical) in random order to assess the efficacy of 140 
non-pharmaceutical agents, against a dual action antihistamine/mast cell stabilizer licensed 141 
for seasonal allergic conjunctivitis. 142 
 143 
Statistics 144 
The randomization code was held by a non-masked researcher and the code broken after 145 
data entry by the statistician. Statistical analysis was performed using SPSS for Microsoft 146 
Windows. As ocular surface temperature and conjunctival hyperemia were found to be 147 
normally distributed (Kolmogorov-Smirnov Test > 0.05), their changes over time were 148 
evaluated by repeated measures Analysis of Variance (ANOVA), and where statistical 149 
significance was identified, post-hoc analysis was performed using paired t-tests. This 150 
approach limited the number of statistical comparisons to minimize the chance of Type I 151 
statistical errors. Changes in ocular symptomology were evaluated by the Friedman test and 152 
post-hoc analysis where statistical significance was identified was performed using Wilcoxon 153 
signed-rank tests. Statistical significance was taken as p < 0.05. Sample size, even of the 154 
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pharmaceutical comparison subgroup, met the requirements for sufficient replicates for a 155 
repeated measures design.19 156 
Results 157 
Non-Pharmaceutical Treatment Efficacy versus No Treatment 158 
Ocular Symptomology 159 
Although the symptoms differed in overall magnitude, with itching rated as the severest 160 
symptom and swelling the least, the profile with time after treatment and recovery was 161 
similar for each of the symptoms so they were averaged for analysis. The global ocular 162 
symptom scores were similar at baseline at each visit (X=6.091, p=0.107) as was the post 163 
exposure effect (X=2.729, p=0.435). They decreased with time after treatment (CC: 164 
X=88.489, p<0.001; AT: X=88.258, p<0.001; AT+CC: X=87.639, p<0.001; Figure 1), with all 165 
treatments reducing symptoms more than no treatment (p < 0.001), but none of the 166 
treatments returned global ocular symptom scores to baseline levels within 1 hour after 167 
antigen exposure (no treatment 58.6% relative return to baseline, CC 71.6%, AT 84.8%, 168 
AT+CC 86.9%; p<0.001). 169 
Bulbar Conjunctival Hyperemia 170 
Hyperemia was similar at baseline at each visit (F=0.955, p=0.438) as was the post 171 
exposure effect (F=0.267, p=0.898). There was no difference in conjunctival hyperemia 172 
between the eyes (F=0.112, p=0.742), however, the nasal conjunctiva was more red than 173 
the temporal conjunctiva over the measurement period (1.71±0.62 versus 1.47±0.56 Jenvis 174 
units; F=33.711, p<0.001). There was a significant difference in conjunctival hyperemia 175 
following each of the treatments (F=68.211, p<0.001; Figure 2), with a reduction in redness 176 
with time (F=302.764, p<0.001), although this recovery differed with treatment (F=9.469, 177 
p<0.001) and none of the treatments achieved complete recovery to baseline within 60 178 
minutes (no treatment 16.5% relative return to baseline, CC 57.9%, AT 73.3%, AT+CC 179 
76.5%; p<0.001). However, all treatments produced a significant improvement in hyperemia 180 
over time compared to no treatment both nasally and temporally (p<0.05). 181 
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Ocular Surface Temperature 182 
Ocular surface temperature was similar at baseline at each visit (F=0.685, p=0.605) as was 183 
the post exposure effect (F=0.636, p=0.639). There was no difference in temperature 184 
between the eyes (F=0.017, p=0.897), however there were significant differences in 185 
temperature between corneal, nasal and temporal locations (F=97.899, p<0.001). There was 186 
a significant difference in temperature following each of the treatments (F=19.684, p<0.001; 187 
Figure 3), with the temperature diconverging toward baseline over time (F=32.955, p<0.001), 188 
although this recovery differed with treatment (F=122.796, p<0.001). Temporal bulbar 189 
conjunctival and corneal temperatures returned to baseline levels (was no longer 190 
significantly different; p>0.05) with the application of cold compress (within 50 minutes), 191 
artificial tears (within 40 minutes) and artificial tears combined with cold compress (within 40 192 
minutes), whereas for the nasal bulbar conjunctiva the return to baseline temperature was 193 
generally faster (40, 30 and 40 minutes respectively). Ocular surface temperature did not 194 
return to baseline levels without treatment at any location (relative return to baseline 57.0%; 195 
p<0.05).  196 
 197 
Relative Efficacy of Non-Pharmaceuticals versus a Dual Action Pharmaceutical  198 
Ocular Symptomology 199 
All ocular symptom changes with time were similar so they have been averaged for 200 
presentation and analysis. At all measurement time intervals, symptoms were reduced for 201 
both EH and EH in combination with a CC compared to a CC or AT alone or in combination 202 
(p < 0.01; Figure 4). Only EH alone and in combination with a CC reduced global ocular 203 
symptom scores to baseline levels within the post-antigen exposure hour over which 204 
subjects were monitored (after 60 minutes: p=0.414, p=0.705). A CC enhanced the 205 
pharmaceutical benefit of EH alone up to 20 minutes (p<0.05), where thereafter they were 206 
similarly efficacious (p>0.05). A CC also further reduced symptoms when combined with AT 207 
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compared to AT use alone up to 20 minutes (p < 0.05). The drug effect was from the active 208 
ingredients rather than the saline vehicle control (p < 0.001).  209 
Bulbar Conjunctival Hyperemia 210 
There was a significant difference in conjunctival hyperemia between each of the treatments 211 
(F=11.728, p<0.001; Table 1), with a reduction in redness with time (F=581.320, p<0.001), 212 
although this recovery differed with treatment (F=9.463, p<0.001). AT combined with CC 213 
outperformed AT, CC and EH alone and EH combined with CC nasally. The treatment effect 214 
of EH was enhanced by combining it with a CC. The saline volume control (vehicle) showed 215 
the action of EH was principally from the active pharmaceutical ingredients. AT instillation 216 
had similar effectiveness to a CC application used in isolation (Table 1).   217 
Ocular Surface Temperature 218 
There was a significant difference in ocular surface temperature between each of the 219 
treatments (F=11.680, p<0.001; Table 2), with a change in temperature toward baseline with 220 
time (F=17.952, p<0.001), although this recovery differed for each treatment (F=144.816, 221 
p<0.001). CC in combination with an AT or EH lowered the antigen-raised ocular surface 222 
temperature below the pre-exposure baseline. AT instillation alone or in combination to a CC 223 
or EH significantly, but only slightly (<0.5ºC), reduced the temperature (p < 0.05; Table 2). 224 
CC combined with either a AT or EH had a similar cooling effect. The saline vehicle volume 225 
control to EH had a similar cooling effect to an AT and no beneficial cooling effect over EH of 226 
the same volume but containing active pharmaceutical agents. 227 
  228 
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Discussion 229 
In the first phase of the study, the efficacy of artificial tears (AT), cold compress (CC) and in 230 
combination (AT+CC) was investigated by measuring conjunctival hyperemia, ocular surface 231 
temperature and ocular symptoms following exposure to grass pollen in an environmental 232 
chamber model to produce the response signs and symptoms of an acute ocular seasonal 233 
allergic conjunctivitis. Subjects were exposed over a 5 minute interval in the environmental 234 
chamber to a predetermined threshold of reactivity, to ensure that subjects had sufficient 235 
signs and symptoms in order to detect any treatment effect. There was no significant 236 
difference in hyperemia, ocular surface temperature or ocular symptoms at each visit 237 
following the multiple exposures separated by at least a week (and between each eye for 238 
hyperemia and ocular surface temperature), demonstrating that the environmental chamber 239 
model produces a bilaterally homogenous and reproducible ocular allergic reaction. The data 240 
show that all treatments provided benefit in relieving hyperemia, restoring physiological 241 
ocular temperature and reducing ocular symptoms during an acute episode of stimulated 242 
SAC compared to no treatment.    243 
 244 
Although artificial tears (AT) are principally formulated to relieve ocular surface signs and 245 
symptoms in dry eye, they have been advocated to have a beneficial effect in SAC 11, 12. The 246 
reduction in signs (conjunctival hyperemia) and symptoms of SAC in this study are likely to 247 
have been principally caused by diluting and washing away the allergen from the eye, and 248 
the AT acting as a barrier to further exposure by preventing the allergen from binding to the 249 
ocular surface 7, 8, 11, 12. This barrier effect to allergens has also been observed in contact lens 250 
wear, where patients wearing soft contact lenses exhibited reduced signs and symptoms of 251 
ocular allergy compared to non-contact lens wearing control visits following exposure in an 252 
allergen chamber, with a further benefit from using contact lenses with sustained release of 253 
a lubricating agent from within the material matrix 20. ATs are generally stored at room 254 
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temperature, which could give them an additional soothing effect, but this study 255 
demonstrated that any benefit from the temperature change from AT is minor compared to 256 
its other properties such as lubrication, with the temperature reduction and consistency over 257 
time higher in the nasal region, compared to the cornea and lower still temporally, following 258 
the excretion pathway of the tear film.  259 
 260 
In environmental studies of anti-allergy drug efficacy, the use of artificial tears as a control 261 
have been shown to have a drug effect of up 50-70% and this is considered to be a placebo 262 
effect 13, 21, 22, 23. However, as artificial tears may produce a real physical effect on the binding 263 
of allergens to the ocular surface, this mechanism cannot be considered purely as placebo 264 
and therefore should not be considered as an effective control in studies of acute SAC, 265 
whereas their use is warranted in investigating the prophylactic effect of an ocular anti-266 
allergy drugs 23. 267 
   268 
The use of cold compresses (CC) has previously been recommended as supportive therapy 269 
in ocular allergy 11, 24, 25 but no studies relating to the efficacy of cold compress treatment has 270 
been reported in the scientific literature. Therefore, this study has demonstrated the 271 
beneficial effects of cold compress therapy in ocular disease for the first time. The 272 
application of CC may reduce hyperemia and relieve signs and symptoms by causing 273 
vasoconstriction of conjunctival blood vessels and subsequently prevent or minimize 274 
swelling and leakage of and inflammatory mediators involved in the allergic response 7, 10, 26. 275 
A potential limitation of the CC data was the ability to control the application to the closed 276 
eyelids, although the gel mask was held in place over the eyes with an attached elastic 277 
headband. This, however, mimicked the clinical reality where the exact area and location of 278 
contact of the compress with the eyelid will vary between patients owing to differences in 279 
facial structure. 280 
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In the second phase of the study, the effectiveness of non-pharmaceutical treatments was 281 
compared to a dual action antihistamine / mast cell stabilizer pharmaceutical (EH), with or 282 
without the addition of a CC, in a randomly selected subgroup of subjects using the same 283 
acute induced-SAC methodology. Comparison over the 60 minute observation period 284 
showed that the combination of artificial tears and cold compress was superior to all other 285 
treatments in reducing hyperemia including over the pharmaceutical agent, although the 286 
antigen induced ocular redness could be improved to the equivalence effectiveness by 287 
combining EH with a CC. An AT or a CC used alone was more effective that the 288 
pharmaceutical used in isolation. The pharmaceutical agent effect, however, was confirmed 289 
as being derived from the active ingredients rather than any ocular lubricating effect of its 290 
fluid vehicle and this was also the case for the pharmaceutical effect on ocular comfort. 291 
 292 
A CC alone or in combination with an AT or EH pharmaceutical lowered the ocular surface 293 
temperature below baseline from the increased level caused by exposure to the antigen, 294 
whereas an AT alone had relatively little effect over ocular temperature, particularly over the 295 
temporal conjunctiva. As this treatment result differed from that of conjunctival hyperemia 296 
and ocular symptoms, it could suggest that the inflammatory events causing increased 297 
ocular surface temperature following antigen exposure could differ from those driving other 298 
signs and symptoms or the results could be confounded by tear film thickness variations 299 
across the ocular surface and with time as this would have affected the radiated heat imaged 300 
by the thermal camera.      301 
 302 
Ocular symptomology improved faster with EH compared to all other treatment modalities, 303 
reducing symptoms to baseline levels after 60 minutes, and the recovery profile was 304 
enhanced initially by the application of a CCs. Although none of the non-pharmaceutical 305 
treatments reduced symptoms to baseline levels, the mean scores were low, falling within 306 
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the “hardly troubled at all” category. These data suggest that AT and CC, either alone or in 307 
combination, are effective methods of relieving the signs and symptoms of SAC during the 308 
active phase of the condition. 309 
 310 
EH displays anti-histamine, anti-inflammatory and mast cell stabilizing properties in animal 311 
and in-vitro studies 27, 28. Conjunctival-allergen-challenge-model clinical trials of EH have 312 
shown that it is significantly more effective in preventing the signs and symptoms of allergic 313 
conjunctivitis compared to its vehicle as confirmed in this study 29, 30. The efficacy of EH has 314 
also been demonstrated to be effective in an environmental clinical trial 31, but these study 315 
designs are subject to variations in exposure and therefore limit their ability to detect the 316 
efficacy of drugs. Thus, there has been a lack of studies investigating the efficacy of EH in 317 
acute SAC. In the present study, the combination of EH combined with CC was superior to 318 
EH alone in reducing ocular surface temperature (p<0.001), superior to EH in reducing 319 
hyperemia both nasally (p<0.001) and temporally (p<0.001), and enhanced the symptom 320 
recovery profile within the first 20 minutes. This suggests that clinically, EH should be 321 
prescribed together with advice on applying cold compresses in acute episodes. EH mast 322 
cell stabilizing properties are only likely to enhance the pharmaceutical effect after a few 323 
days use which should be considered if the patient is likely to be exposed to multiple 324 
episodes of acute pollen exposure over a short time period. 325 
  326 
The results of the present study are applicable only on the ability of the treatments to relieve 327 
the signs and symptoms of simulated SAC during the acute phase of the ocular allergic 328 
response, thus it has no bearing on their ability to prevent signs and symptoms from 329 
developing through prophylactic treatment. It is not expected that the application of cold 330 
compress or artificial tears will have any effect before the ocular allergic response develops, 331 
unless they are applied frequently. These data suggest that although EH resolves symptoms 332 
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of SAC earlier, it appears to be less efficacious in resolving ocular signs of inflammation 333 
such as conjunctival hyperemia and ocular surface temperature increases compared to an 334 
artificial tear or cold compress alone, or better in combination, during an acute episode of 335 
SAC. Therefore for occasional sufferers such self-management, with reduced risks of drug 336 
interactions and reduced patient expense, should be considered. For more frequent SAC 337 
sufferers, the benefits of a cold compress in addition to prophylactic pharmaceuticals should 338 
be considered as part of patient management when symptoms still occur. Further study is 339 
required to measure the immunologic response to ocular signs and symptoms induced by 340 
the environmental chamber and treatment strategies.       341 
Word Count: 3,257 342 
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Abstract 24 
Objective: To investigate whether artificial tears and cold compress alone or in combination 25 
provide a treatment benefit, whether they were as effective as, or could enhance topical anti-26 
allergic medication.   27 
Design: Randomized masked clinical trial. 28 
Participants: Eighteen subjects (aged 29.5 ± 11.0 years) allergic to grass pollen  29 
Intervention: Controlled exposure to grass pollen using an environmental chamber to 30 
stimulate an ocular allergic reaction followed by artificial tears (AT), 5 minutes of cold 31 
compress (CC), AT combined with CC, or no treatment applied at each separate visit in 32 
random order. A subset of 11 subjects also had epinastine (EH) applied alone and combined 33 
with CC in random order or instillation of a volume matched saline control.   34 
Main Outcome Measures: bulbar conjunctival hyperemia, ocular surface temperature, ocular 35 
symptoms repeated before and every 10 minutes after treatment for 1 hour 36 
Results: Bulbar conjunctival hyperemia and ocular symptoms decreased and temperature 37 
recovered to baseline faster with non-pharmaceutical treatments compared to no treatment 38 
(p < 0.05). AT combined with CC reduced hyperemia more than other treatments (p < 0.05). 39 
The treatment effect of EH was enhanced by combining it with a CC (p < 0.001). CC 40 
combined with AT or EH lowered the antigen-raised ocular surface temperature below the 41 
pre-exposure baseline. AT instillation alone or CC combined with AT or EH significantly 42 
reduced the temperature (p < 0.05). CC combined with AT or EH had a similar cooling effect 43 
(p > 0.05). At all measurement time intervals, symptoms were reduced for both EH and EH 44 
combined with CC than CC or AT alone or in combination (p < 0.014).  45 
Conclusions: In a controlled exposure to grass pollen, cold compresses and artificial tears 46 
showed therapeutic effect on the signs and symptoms of allergic conjunctivitis. A cold 47 
compress enhanced the use of epinastine alone and was the only treatment to reduce 48 
symptoms to baseline within an hour of antigenic challenge. Signs of allergic conjunctivitis 49 
were generally reduced most by a combination of a cold compress in combination with 50 
artificial tears or epinastine. 51 
  52 
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Ocular allergy represents a group of hypersensitivity disorders that primarily affects the 53 
conjunctiva. The most common form of ocular allergy is seasonal allergic conjunctivitis 54 
(SAC), accounting for 90% of cases 1, 2. The most prevalent allergens in SAC are grass, tree, 55 
and weed pollen and outdoor moulds 2.  In the United Kingdom (UK), the prevalence of 56 
ocular allergy to grass pollen in patients attending optometric practice is estimated to be 8% 57 
3. Although the signs and symptoms of SAC are usually mild, it may hinder school 58 
performance, work productivity and everyday tasks such as driving 4, 5, 6. 59 
  60 
The primary treatment strategy for SAC involves avoidance of the offending allergen to 61 
prevent the initiation of the allergic response. However, complete avoidance is not often 62 
possible and use of topical anti-allergic medications is required when signs and symptoms 63 
occur 7, 8, 9. It has been suggested that non-pharmacological treatments such as artificial 64 
tears and cold compresses may be used in conjunction with allergen avoidance strategies 65 
and anti-allergic medications to help bring about symptomatic relief 9, 10, 11, 12. However, there 66 
appears to be no evidence in the scientific literature which demonstrates the efficacy of 67 
using artificial tears or cold compresses for treating SAC. Therefore the aim of this study was 68 
to investigate the efficacy of instillation of artificial tear substitutes (AT) and application of 69 
cold compresses (CC) alone and in combination in patients with confirmed ocular allergic 70 
sensitivity to a controlled exposure of grass pollen using an environmental chamber model. 71 
In addition, the effectiveness of these treatments compared to a topical dual action 72 
antihistamine-mast cell stabilizer licensed for the treatment of SAC alone and in combination 73 
with CC was investigated.  74 
 75 
  76 
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Materials and Methods 77 
The study received ethical approval from the Aston University Research Ethics Committee 78 
and was registered as a clinical trial (NCT01569191 ClinicalTrials.gov). The research was 79 
conducted in accordance this the principles expressed in the Declaration of Helsinki. 80 
 81 
Subjects  82 
All participants were ≥18 years old volunteers from a University population with no history of 83 
asthma, any active eye pathology and were not using ocular or systemic medications known 84 
to affect the eye. None of the participants experienced any form of allergic conjunctivitis at 85 
least 1 month before the study took place or used anti-allergic medication over the 14 days 86 
prior to testing.  87 
 88 
Screening Protocol 89 
Subjects underwent skin prick (SPT) and bilateral conjunctival challenge tests (CCT) to 90 
confirm systemic and ocular allergic sensitivity to grass pollen 13, 14, 15 . SPT was performed 91 
on the forearm using grass pollen solution (10 HEP, Soluprick SQ, ALK-ABELLO, Denmark) 92 
and positive (histamine solution) and negative (saline) controls. After 20 minutes, the size of 93 
the wheal response was measured and a positive result was recorded for diameters ≥3mm.  94 
CCT was performed by applying 20µL of grass pollen (Soluprick SQ, ALK-ABELLO, 95 
Denmark) solution in two-fold increasing concentrations from 3IR/mL to 100IR/mL to one eye 96 
(selected at random to be the experimental eye) and saline solution to the contralateral 97 
(control) eye every 10 minutes until a composite score of ≥5 using a standardized scoring 98 
method was reached 13, 14, 16.  Eligible subjects who had a positive SPT and CCT proved 99 
sensitivity to grass pollen were enrolled into the study with written informed consent.  100 
 101 
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Eighteen subjects (one third male) took part in the study with a mean age of 29.5±11.0 (age 102 
range 20-65). At each visit subjects underwent slit lamp bio-microscopy to ensure signs and 103 
symptoms of SAC were not present prior to testing. This was followed by a series of 104 
measurements on both eyes including slit lamp examination and grading of nasal and 105 
temporal bulbar conjunctival hyperemia using a grading scale (Jenvis Research, Germany), 106 
and ocular surface temperature of the cornea and temporal and nasal bulbar conjunctiva 107 
(5mm2 area, 2 seconds post-blink) using an infra-red camera (Thermo Tracer TH7102, NEC, 108 
Japan) where a series of digital markers were used to ensure the temperature was 109 
measured at the same location for each subject17. Ocular allergy symptomology was also 110 
measured using the eye symptom section from the Rhinoconjunctivitis Quality of Life 111 
Questionnaire (RQLQ) on a 0 to 6 scale, with the summed score for itching, watering, 112 
swelling and soreness resulting in a score between 0 and 24  18.  113 
 114 
Subjects were exposed to between 251 and 500 grains/m3 of Timothy grass pollen (phleum 115 
pratense; equivalent to a “very high” pollen count classification; concentration monitored 116 
using a Burkard continuous air sampler) in a computer controlled environmental chamber 117 
(Design Environmental, 32 Rassau Industrial Estate, Ebbw Vale, Gwent) at a temperature of 118 
20°C and 70% ambient humidity (average local conditions in June in the UK) on separate 119 
visits with the concentration established that caused ocular itching graded ≥3 (RQLQ grade) 120 
and a ≥0.5 unit change (Jenvis scale) in nasal and temporal bulbar conjunctival hyperemia 121 
occurred in both eyes after 5 minutes of exposure.  122 
 123 
Once the concentration of pollen for each individual had been established, on separate 124 
occasions separated by at least one week, out of the allergy season, the subjects had 125 
baseline measurements taken and were then exposed to pollen at this concentration for 5 126 
minutes and 5 minutes post exposure the same measurements were repeated. This was 127 
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followed by application bilaterally of either an AT applied to the temporal conjunctiva (Blink 128 
Refreshing Eye Drops 0.5ml single use vial, Abbot Medical Optics, USA), CC applied to the 129 
closed eye lid for 5 minutes (frozen gel-pack: Boots Pharmaceuticals, Nottingham, UK), AT 130 
combined with CC (for 5 minutes, 5 minutes after AT instillation) or no treatment (NT) to the 131 
eyes in random order (computer generated) at each visit (examiner masked). The same 132 
measures were then repeated every 10 minutes for 1 hour at each visit.  133 
 134 
A subgroup of 11 randomly selected subjects (mean age of 29.1±12.9 years, range 20-65) 135 
attended for three further identical visits receiving 1 drop of Epinastine Hydrochloride (EH, 136 
Relestat 0.5mg/ml, Allergan, USA), 1 drop of EH combined with CC (for 5 minutes, 5 137 
minutes after instillation of EH), or a single drop of saline (termed vehicle, equivalent to the 138 
same volume as the drug but without the active ingredients to determine how much of the 139 
effect was lubrication compared to pharmaceutical) in random order to assess the efficacy of 140 
non-pharmaceutical agents, against a dual action antihistamine/mast cell stabilizer licensed 141 
for seasonal allergic conjunctivitis. 142 
 143 
Statistics 144 
The randomization code was held by a non-masked researcher and the code broken after 145 
data entry by the statistician. Statistical analysis was performed using SPSS for Microsoft 146 
Windows. As ocular surface temperature and conjunctival hyperemia were found to be 147 
normally distributed (Kolmogorov-Smirnov Test > 0.05), their changes over time were 148 
evaluated by repeated measures Analysis of Variance (ANOVA), and where statistical 149 
significance was identified, post-hoc analysis was performed using paired t-tests. This 150 
approach limited the number of statistical comparisons to minimize the chance of Type I 151 
statistical errors. Changes in ocular symptomology were evaluated by the Friedman test and 152 
post-hoc analysis where statistical significance was identified was performed using Wilcoxon 153 
signed-rank tests. Statistical significance was taken as p < 0.05. Sample size, even of the 154 
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pharmaceutical comparison subgroup, met the requirements for sufficient replicates for a 155 
repeated measures design.19 156 
Results 157 
Non-Pharmaceutical Treatment Efficacy versus No Treatment 158 
Ocular Symptomology 159 
Although the symptoms differed in overall magnitude, with itching rated as the severest 160 
symptom and swelling the least, the profile with time after treatment and recovery was 161 
similar for each of the symptoms so they were averaged for analysis. The global ocular 162 
symptom scores were similar at baseline at each visit (X=6.091, p=0.107) as was the post 163 
exposure effect (X=2.729, p=0.435). They decreased with time after treatment (CC: 164 
X=88.489, p<0.001; AT: X=88.258, p<0.001; AT+CC: X=87.639, p<0.001; Figure 1), with all 165 
treatments reducing symptoms more than no treatment (p < 0.001), but none of the 166 
treatments returned global ocular symptom scores to baseline levels within 1 hour after 167 
antigen exposure (no treatment 58.6% relative return to baseline, CC 71.6%, AT 84.8%, 168 
AT+CC 86.9%; p<0.001). 169 
Bulbar Conjunctival Hyperemia 170 
Hyperemia was similar at baseline at each visit (F=0.955, p=0.438) as was the post 171 
exposure effect (F=0.267, p=0.898). There was no difference in conjunctival hyperemia 172 
between the eyes (F=0.112, p=0.742), however, the nasal conjunctiva was more red than 173 
the temporal conjunctiva over the measurement period (1.71±0.62 versus 1.47±0.56 Jenvis 174 
units; F=33.711, p<0.001). There was a significant difference in conjunctival hyperemia 175 
following each of the treatments (F=68.211, p<0.001; Figure 2), with a reduction in redness 176 
with time (F=302.764, p<0.001), although this recovery differed with treatment (F=9.469, 177 
p<0.001) and none of the treatments achieved complete recovery to baseline within 60 178 
minutes (no treatment 16.5% relative return to baseline, CC 57.9%, AT 73.3%, AT+CC 179 
76.5%; p<0.001). However, all treatments produced a significant improvement in hyperemia 180 
over time compared to no treatment both nasally and temporally (p<0.05). 181 
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Ocular Surface Temperature 182 
Ocular surface temperature was similar at baseline at each visit (F=0.685, p=0.605) as was 183 
the post exposure effect (F=0.636, p=0.639). There was no difference in temperature 184 
between the eyes (F=0.017, p=0.897), however there were significant differences in 185 
temperature between corneal, nasal and temporal locations (F=97.899, p<0.001). There was 186 
a significant difference in temperature following each of the treatments (F=19.684, p<0.001; 187 
Figure 3), with the temperature converging toward baseline over time (F=32.955, p<0.001), 188 
although this recovery differed with treatment (F=122.796, p<0.001). Temporal bulbar 189 
conjunctival and corneal temperatures returned to baseline levels (was no longer 190 
significantly different; p>0.05) with the application of cold compress (within 50 minutes), 191 
artificial tears (within 40 minutes) and artificial tears combined with cold compress (within 40 192 
minutes), whereas for the nasal bulbar conjunctiva the return to baseline temperature was 193 
generally faster (40, 30 and 40 minutes respectively). Ocular surface temperature did not 194 
return to baseline levels without treatment at any location (relative return to baseline 57.0%; 195 
p<0.05).  196 
 197 
Relative Efficacy of Non-Pharmaceuticals versus a Dual Action Pharmaceutical  198 
Ocular Symptomology 199 
All ocular symptom changes with time were similar so they have been averaged for 200 
presentation and analysis. At all measurement time intervals, symptoms were reduced for 201 
both EH and EH in combination with a CC compared to a CC or AT alone or in combination 202 
(p < 0.01; Figure 4). Only EH alone and in combination with a CC reduced global ocular 203 
symptom scores to baseline levels within the post-antigen exposure hour over which 204 
subjects were monitored (after 60 minutes: p=0.414, p=0.705). A CC enhanced the 205 
pharmaceutical benefit of EH alone up to 20 minutes (p<0.05), where thereafter they were 206 
similarly efficacious (p>0.05). A CC also further reduced symptoms when combined with AT 207 
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compared to AT use alone up to 20 minutes (p < 0.05). The drug effect was from the active 208 
ingredients rather than the saline vehicle control (p < 0.001).  209 
Bulbar Conjunctival Hyperemia 210 
There was a significant difference in conjunctival hyperemia between each of the treatments 211 
(F=11.728, p<0.001; Table 1), with a reduction in redness with time (F=581.320, p<0.001), 212 
although this recovery differed with treatment (F=9.463, p<0.001). AT combined with CC 213 
outperformed AT, CC and EH alone and EH combined with CC nasally. The treatment effect 214 
of EH was enhanced by combining it with a CC. The saline volume control (vehicle) showed 215 
the action of EH was principally from the active pharmaceutical ingredients. AT instillation 216 
had similar effectiveness to a CC application used in isolation (Table 1).   217 
Ocular Surface Temperature 218 
There was a significant difference in ocular surface temperature between each of the 219 
treatments (F=11.680, p<0.001; Table 2), with a change in temperature toward baseline with 220 
time (F=17.952, p<0.001), although this recovery differed for each treatment (F=144.816, 221 
p<0.001). CC in combination with an AT or EH lowered the antigen-raised ocular surface 222 
temperature below the pre-exposure baseline. AT instillation alone or in combination to a CC 223 
or EH significantly, but only slightly (<0.5ºC), reduced the temperature (p < 0.05; Table 2). 224 
CC combined with either a AT or EH had a similar cooling effect. The saline vehicle volume 225 
control to EH had a similar cooling effect to an AT and no beneficial cooling effect over EH of 226 
the same volume but containing active pharmaceutical agents. 227 
  228 
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Discussion 229 
In the first phase of the study, the efficacy of artificial tears (AT), cold compress (CC) and in 230 
combination (AT+CC) was investigated by measuring conjunctival hyperemia, ocular surface 231 
temperature and ocular symptoms following exposure to grass pollen in an environmental 232 
chamber model to produce the response signs and symptoms of an acute ocular seasonal 233 
allergic conjunctivitis. Subjects were exposed over a 5 minute interval in the environmental 234 
chamber to a predetermined threshold of reactivity, to ensure that subjects had sufficient 235 
signs and symptoms in order to detect any treatment effect. There was no significant 236 
difference in hyperemia, ocular surface temperature or ocular symptoms at each visit 237 
following the multiple exposures separated by at least a week (and between each eye for 238 
hyperemia and ocular surface temperature), demonstrating that the environmental chamber 239 
model produces a bilaterally homogenous and reproducible ocular allergic reaction. The data 240 
show that all treatments provided benefit in relieving hyperemia, restoring physiological 241 
ocular temperature and reducing ocular symptoms during an acute episode of stimulated 242 
SAC compared to no treatment.    243 
 244 
Although artificial tears (AT) are principally formulated to relieve ocular surface signs and 245 
symptoms in dry eye, they have been advocated to have a beneficial effect in SAC 11, 12. The 246 
reduction in signs (conjunctival hyperemia) and symptoms of SAC in this study are likely to 247 
have been principally caused by diluting and washing away the allergen from the eye, and 248 
the AT acting as a barrier to further exposure by preventing the allergen from binding to the 249 
ocular surface 7, 8, 11, 12. This barrier effect to allergens has also been observed in contact lens 250 
wear, where patients wearing soft contact lenses exhibited reduced signs and symptoms of 251 
ocular allergy compared to non-contact lens wearing control visits following exposure in an 252 
allergen chamber, with a further benefit from using contact lenses with sustained release of 253 
a lubricating agent from within the material matrix 20. ATs are generally stored at room 254 
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temperature, which could give them an additional soothing effect, but this study 255 
demonstrated that any benefit from the temperature change from AT is minor compared to 256 
its other properties such as lubrication, with the temperature reduction and consistency over 257 
time higher in the nasal region, compared to the cornea and lower still temporally, following 258 
the excretion pathway of the tear film.  259 
 260 
In environmental studies of anti-allergy drug efficacy, the use of artificial tears as a control 261 
have been shown to have a drug effect of up 50-70% and this is considered to be a placebo 262 
effect 13, 21, 22, 23. However, as artificial tears may produce a real physical effect on the binding 263 
of allergens to the ocular surface, this mechanism cannot be considered purely as placebo 264 
and therefore should not be considered as an effective control in studies of acute SAC, 265 
whereas their use is warranted in investigating the prophylactic effect of an ocular anti-266 
allergy drugs 23. 267 
   268 
The use of cold compresses (CC) has previously been recommended as supportive therapy 269 
in ocular allergy 11, 24, 25 but no studies relating to the efficacy of cold compress treatment has 270 
been reported in the scientific literature. Therefore, this study has demonstrated the 271 
beneficial effects of cold compress therapy in ocular disease for the first time. The 272 
application of CC may reduce hyperemia and relieve signs and symptoms by causing 273 
vasoconstriction of conjunctival blood vessels and subsequently prevent or minimize 274 
swelling and leakage of and inflammatory mediators involved in the allergic response 7, 10, 26. 275 
A potential limitation of the CC data was the ability to control the application to the closed 276 
eyelids, although the gel mask was held in place over the eyes with an attached elastic 277 
headband. This, however, mimicked the clinical reality where the exact area and location of 278 
contact of the compress with the eyelid will vary between patients owing to differences in 279 
facial structure. 280 
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In the second phase of the study, the effectiveness of non-pharmaceutical treatments was 281 
compared to a dual action antihistamine / mast cell stabilizer pharmaceutical (EH), with or 282 
without the addition of a CC, in a randomly selected subgroup of subjects using the same 283 
acute induced-SAC methodology. Comparison over the 60 minute observation period 284 
showed that the combination of artificial tears and cold compress was superior to all other 285 
treatments in reducing hyperemia including over the pharmaceutical agent, although the 286 
antigen induced ocular redness could be improved to the equivalence effectiveness by 287 
combining EH with a CC. An AT or a CC used alone was more effective that the 288 
pharmaceutical used in isolation. The pharmaceutical agent effect, however, was confirmed 289 
as being derived from the active ingredients rather than any ocular lubricating effect of its 290 
fluid vehicle and this was also the case for the pharmaceutical effect on ocular comfort. 291 
 292 
A CC alone or in combination with an AT or EH pharmaceutical lowered the ocular surface 293 
temperature below baseline from the increased level caused by exposure to the antigen, 294 
whereas an AT alone had relatively little effect over ocular temperature, particularly over the 295 
temporal conjunctiva. As this treatment result differed from that of conjunctival hyperemia 296 
and ocular symptoms, it could suggest that the inflammatory events causing increased 297 
ocular surface temperature following antigen exposure could differ from those driving other 298 
signs and symptoms or the results could be confounded by tear film thickness variations 299 
across the ocular surface and with time as this would have affected the radiated heat imaged 300 
by the thermal camera.      301 
 302 
Ocular symptomology improved faster with EH compared to all other treatment modalities, 303 
reducing symptoms to baseline levels after 60 minutes, and the recovery profile was 304 
enhanced initially by the application of a CCs. Although none of the non-pharmaceutical 305 
treatments reduced symptoms to baseline levels, the mean scores were low, falling within 306 
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the “hardly troubled at all” category. These data suggest that AT and CC, either alone or in 307 
combination, are effective methods of relieving the signs and symptoms of SAC during the 308 
active phase of the condition. 309 
 310 
EH displays anti-histamine, anti-inflammatory and mast cell stabilizing properties in animal 311 
and in-vitro studies 27, 28. Conjunctival-allergen-challenge-model clinical trials of EH have 312 
shown that it is significantly more effective in preventing the signs and symptoms of allergic 313 
conjunctivitis compared to its vehicle as confirmed in this study 29, 30. The efficacy of EH has 314 
also been demonstrated to be effective in an environmental clinical trial 31, but these study 315 
designs are subject to variations in exposure and therefore limit their ability to detect the 316 
efficacy of drugs. Thus, there has been a lack of studies investigating the efficacy of EH in 317 
acute SAC. In the present study, the combination of EH combined with CC was superior to 318 
EH alone in reducing ocular surface temperature (p<0.001), superior to EH in reducing 319 
hyperemia both nasally (p<0.001) and temporally (p<0.001), and enhanced the symptom 320 
recovery profile within the first 20 minutes. This suggests that clinically, EH should be 321 
prescribed together with advice on applying cold compresses in acute episodes. EH mast 322 
cell stabilizing properties are only likely to enhance the pharmaceutical effect after a few 323 
days use which should be considered if the patient is likely to be exposed to multiple 324 
episodes of acute pollen exposure over a short time period. 325 
  326 
The results of the present study are applicable only on the ability of the treatments to relieve 327 
the signs and symptoms of simulated SAC during the acute phase of the ocular allergic 328 
response, thus it has no bearing on their ability to prevent signs and symptoms from 329 
developing through prophylactic treatment. It is not expected that the application of cold 330 
compress or artificial tears will have any effect before the ocular allergic response develops, 331 
unless they are applied frequently. These data suggest that although EH resolves symptoms 332 
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of SAC earlier, it appears to be less efficacious in resolving ocular signs of inflammation 333 
such as conjunctival hyperemia and ocular surface temperature increases compared to an 334 
artificial tear or cold compress alone, or better in combination, during an acute episode of 335 
SAC. Therefore for occasional sufferers such self-management, with reduced risks of drug 336 
interactions and reduced patient expense, should be considered. For more frequent SAC 337 
sufferers, the benefits of a cold compress in addition to prophylactic pharmaceuticals should 338 
be considered as part of patient management when symptoms still occur. Further study is 339 
required to measure the immunologic response to ocular signs and symptoms induced by 340 
the environmental chamber and treatment strategies.       341 
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Table 1: Statistical comparison of nasal (n) and temporal (t) hyperemia between the non-
pharmaceutical and pharmaceutical treatments. 
  
Significance (p) 
Treatment Mean* EH EH+CC CC AT AT+CC Vehicle 
EH 
1.46±0.43n X <0.001 0.378 0.045 0.042 <0.001 
1.35±0.40t X <0.001 <0.001 <0.001 <0.001 <0.001 
EH+CC 
1.33±0.41n   X 0.002 <0.001 0.559 <0.001 
1.19±0.37t   X 0.929 0.220 0.014 <0.001 
CC 
1.51±0.30n   
 
X 0.349 <0.001 <0.001 
1.19±0.29t     X 0.162 <0.001 <0.001 
AT 
1.55±0.38n   
  
X <0.001 <0.001 
1.24±0.35t       X <0.001 <0.001 
AT+CC 
1.36±0.31n   
   
X <0.001 
1.08±0.37t         X <0.001 
Vehicle 
2.00±0.39n   
    
X 
1.65±0.38t           X 
 
Treatments: epinastine hydrochloride (EH), epinastine hydrochloride combined with cold 
compress (EH+CC), cold compress (CC), artificial tear (AT), artificial tears combined with 
cold compress (AT+CC) and vehicle. Nasal and temporal regions significantly interacted with 
treatment and so have been presented separately.* = mean hyperaemia grade (Jenvis units) 
of right and left eyes averaged (n=11, 22 eyes) over 60 minutes. 
  
Table
Click here to download Table: Tables.docx
 Table 2: Statistical comparison of ocular surface temperature between the non-
pharmaceutical and pharmaceutical treatments. 
  
Significance (p) 
Treatment Mean* EH EH+CC CC AT AT+CC Vehicle 
EH 35.31±0.48 X <0.001 <0.001 <0.001 <0.001 0.057 
EH+CC 34.72±0.63   X 0.228 <0.001 0.089 <0.001 
CC 34.81±0.55     X <0.001 <0.001 <0.001 
AT 35.52±0.67       X <0.001 0.319 
AT+CC 34.57±0.34         X <0.001 
Vehicle 35.44±0.41           X 
 
Treatments: epinastine hydrochloride (EH), epinastine hydrochloride combined with cold 
compress (EH+CC), cold compress (CC), artificial tear (AT), artificial tears combined with 
cold compress (AT+CC) and vehicle. Ocular temperature was similar between eyes and did 
not interact with ocular surface region, so average data is presented. * = mean ocular 
surface temperature of right and left eyes and region combined (n=11, 22 eyes) over 60 
minutes. 
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Figures Legends 
Figure 1: Ocular symptoms pre and post pollen exposure and every 10 minutes thereafter 
up to 60 minutes for no treatment, cold compress, artificial tears and artificial tears combined 
with cold compress. Although the symptoms differed in overall magnitude the profile with 
time after treatment and recovery was similar for each of the symptoms so they were 
averaged for analysis. n = 18. Error bars represent ±1 standard deviation.  
 
Figure 2: Hyperemia grade pre and post pollen exposure and every 10 minutes thereafter 
up to 60 minutes for no treatment, cold compress, artificial tears and artificial tears combined 
with cold compress on the temporal and nasal bulbar conjunctiva. Data from right and left 
eyes were similar so were averaged (n=18 subjects, 36 eyes). Error bars represent ±1 
standard deviation. 
 
Figure 3: Ocular surface temperature pre and post pollen exposure and every 10 minutes 
thereafter up to 60 minutes for no treatment, cold compress, artificial tears and artificial tears 
combined with cold compress on the corneal and temporal and nasal bulbar conjunctival 
surfaces. Data from right and left eyes were similar so were averaged (n=18 subjects, 36 
eyes). Error bars represent ±1 standard deviation. 
 
Figure 4: Ocular symptoms pre and post pollen exposure and every 10 minutes thereafter 
up to 60 minutes for the saline vehicle volume control, cold compress, artificial tears and 
artificial tears combined with cold compress, epinastine hydrochloride (HCL) and epinastine 
HCL combined with a cold compress. Although the symptoms differed in overall magnitude 
the profile with time after treatment and recovery was similar for each of the symptoms so 
they were averaged for analysis. n = 11. Error bars represent ±1 standard deviation.  
Legends
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Ophthalmology Study Design Worksheet #1 
Randomized Controlled Trial (RCT) 
Ophthalmology requires compliance with the CONSORT statement (Begg C, Cho M, 
Eastwoods S, et al. Improving the quality of reporting of randomized controlled trials: the 
CONSORT statement. JAMA 1996;276:637-9. See also JAMA, 1997;227:76-7). 
Randomized (controlled) trial. A human trial that involves at least one experimental 
treatment group and one control treatment group, concurrent enrollment, and follow-up of the 
test and control groups, and in which the assignment to experimental and control groups is by 
a randomization process. Neither the subjects nor the persons responsible for treatment can 
influence the assignments, and the assignments remain unknown to the subjects and staff 
until eligibility has been determined. 
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